Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: Antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups

JSHCT GVHD Working Group

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    Graft-versus-host disease-free relapse-free survival, which is defined as the absence of grade III-IV acute graft-versus-host disease, systemically treated chronic graft-versus-host disease, relapse, and death, is a novel, meaningful composite end point for clinical trials. To characterize risk factors and differences in graft-versus-host disease-free relapse-free survival according to a variety of graft sources, we analyzed 23, 302 patients with hematologic malignancy that had a first allogeneic transplantation from 2000 through 2013 using the Japanese national transplant registry database. The 1-year graft-versus-host disease-free relapsefree survival rate was 41% in all patients. The rate was higher after bone marrow transplantation than after peripheral blood stem cell transplantation due to the lower risks of III-IV acute and chronic graft-versus-host disease. The rate was highest after HLA-matched sibling bone marrow transplantation. The rate after single cord blood transplantation was comparable to that after HLA-matched unrelated bone marrow transplantation among patients aged 20 years or under, and was comparable or better than other alternative graft sources among patients aged 21 years or over, due to the low risk of chronic graft-versus-host disease. Other factors associated with better graft-versus-host disease-free relapse-free survival include female patients, antithymocyte globulin prophylaxis (for standard-risk disease), recent years of transplantation, sex combinations other than from a female donor to a male patient, the absence of prior autologous transplantation, myeloablative conditioning, negative cytomegalovirus serostatus, and tacrolimus-based prophylaxis. These results provide important information to guide the choice of graft sources and are benchmarks for future graft-versus-host disease prophylaxis studies.

    Original languageEnglish
    Pages (from-to)1592-1602
    Number of pages11
    JournalHaematologica
    Volume101
    Issue number12
    DOIs
    Publication statusPublished - Jan 1 2016

    Fingerprint

    Antilymphocyte Serum
    Graft vs Host Disease
    Fetal Blood
    Transplants
    Recurrence
    Survival
    Bone Marrow Transplantation
    Transplantation Conditioning
    Transplantation
    Peripheral Blood Stem Cell Transplantation
    Benchmarking
    Autologous Transplantation
    Homologous Transplantation
    Tacrolimus
    Hematologic Neoplasms
    Cytomegalovirus
    Disease-Free Survival
    Registries
    Siblings
    Survival Rate

    All Science Journal Classification (ASJC) codes

    • Hematology

    Cite this

    @article{fdf99c734b524fb8830c61093b70fa93,
    title = "Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: Antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups",
    abstract = "Graft-versus-host disease-free relapse-free survival, which is defined as the absence of grade III-IV acute graft-versus-host disease, systemically treated chronic graft-versus-host disease, relapse, and death, is a novel, meaningful composite end point for clinical trials. To characterize risk factors and differences in graft-versus-host disease-free relapse-free survival according to a variety of graft sources, we analyzed 23, 302 patients with hematologic malignancy that had a first allogeneic transplantation from 2000 through 2013 using the Japanese national transplant registry database. The 1-year graft-versus-host disease-free relapsefree survival rate was 41{\%} in all patients. The rate was higher after bone marrow transplantation than after peripheral blood stem cell transplantation due to the lower risks of III-IV acute and chronic graft-versus-host disease. The rate was highest after HLA-matched sibling bone marrow transplantation. The rate after single cord blood transplantation was comparable to that after HLA-matched unrelated bone marrow transplantation among patients aged 20 years or under, and was comparable or better than other alternative graft sources among patients aged 21 years or over, due to the low risk of chronic graft-versus-host disease. Other factors associated with better graft-versus-host disease-free relapse-free survival include female patients, antithymocyte globulin prophylaxis (for standard-risk disease), recent years of transplantation, sex combinations other than from a female donor to a male patient, the absence of prior autologous transplantation, myeloablative conditioning, negative cytomegalovirus serostatus, and tacrolimus-based prophylaxis. These results provide important information to guide the choice of graft sources and are benchmarks for future graft-versus-host disease prophylaxis studies.",
    author = "{JSHCT GVHD Working Group} and Yoshihiro Inamoto and Fumihiko Kimura and Junya Kanda and Junichi Sugita and Kazuhiro Ikegame and Hideki Nakasone and Yasuhito Nannya and Naoyuki Uchida and Takahiro Fukuda and Kosuke Yoshioka and Yukiyasu Ozawa and Ichiro Kawano and Yoshiko Atsuta and Koji Kato and Koji Kato and Masami Inoue and Takanori Teshima",
    year = "2016",
    month = "1",
    day = "1",
    doi = "10.3324/haematol.2016.149427",
    language = "English",
    volume = "101",
    pages = "1592--1602",
    journal = "Haematologica",
    issn = "0390-6078",
    publisher = "Ferrata Storti Foundation",
    number = "12",

    }

    TY - JOUR

    T1 - Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources

    T2 - Antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups

    AU - JSHCT GVHD Working Group

    AU - Inamoto, Yoshihiro

    AU - Kimura, Fumihiko

    AU - Kanda, Junya

    AU - Sugita, Junichi

    AU - Ikegame, Kazuhiro

    AU - Nakasone, Hideki

    AU - Nannya, Yasuhito

    AU - Uchida, Naoyuki

    AU - Fukuda, Takahiro

    AU - Yoshioka, Kosuke

    AU - Ozawa, Yukiyasu

    AU - Kawano, Ichiro

    AU - Atsuta, Yoshiko

    AU - Kato, Koji

    AU - Kato, Koji

    AU - Inoue, Masami

    AU - Teshima, Takanori

    PY - 2016/1/1

    Y1 - 2016/1/1

    N2 - Graft-versus-host disease-free relapse-free survival, which is defined as the absence of grade III-IV acute graft-versus-host disease, systemically treated chronic graft-versus-host disease, relapse, and death, is a novel, meaningful composite end point for clinical trials. To characterize risk factors and differences in graft-versus-host disease-free relapse-free survival according to a variety of graft sources, we analyzed 23, 302 patients with hematologic malignancy that had a first allogeneic transplantation from 2000 through 2013 using the Japanese national transplant registry database. The 1-year graft-versus-host disease-free relapsefree survival rate was 41% in all patients. The rate was higher after bone marrow transplantation than after peripheral blood stem cell transplantation due to the lower risks of III-IV acute and chronic graft-versus-host disease. The rate was highest after HLA-matched sibling bone marrow transplantation. The rate after single cord blood transplantation was comparable to that after HLA-matched unrelated bone marrow transplantation among patients aged 20 years or under, and was comparable or better than other alternative graft sources among patients aged 21 years or over, due to the low risk of chronic graft-versus-host disease. Other factors associated with better graft-versus-host disease-free relapse-free survival include female patients, antithymocyte globulin prophylaxis (for standard-risk disease), recent years of transplantation, sex combinations other than from a female donor to a male patient, the absence of prior autologous transplantation, myeloablative conditioning, negative cytomegalovirus serostatus, and tacrolimus-based prophylaxis. These results provide important information to guide the choice of graft sources and are benchmarks for future graft-versus-host disease prophylaxis studies.

    AB - Graft-versus-host disease-free relapse-free survival, which is defined as the absence of grade III-IV acute graft-versus-host disease, systemically treated chronic graft-versus-host disease, relapse, and death, is a novel, meaningful composite end point for clinical trials. To characterize risk factors and differences in graft-versus-host disease-free relapse-free survival according to a variety of graft sources, we analyzed 23, 302 patients with hematologic malignancy that had a first allogeneic transplantation from 2000 through 2013 using the Japanese national transplant registry database. The 1-year graft-versus-host disease-free relapsefree survival rate was 41% in all patients. The rate was higher after bone marrow transplantation than after peripheral blood stem cell transplantation due to the lower risks of III-IV acute and chronic graft-versus-host disease. The rate was highest after HLA-matched sibling bone marrow transplantation. The rate after single cord blood transplantation was comparable to that after HLA-matched unrelated bone marrow transplantation among patients aged 20 years or under, and was comparable or better than other alternative graft sources among patients aged 21 years or over, due to the low risk of chronic graft-versus-host disease. Other factors associated with better graft-versus-host disease-free relapse-free survival include female patients, antithymocyte globulin prophylaxis (for standard-risk disease), recent years of transplantation, sex combinations other than from a female donor to a male patient, the absence of prior autologous transplantation, myeloablative conditioning, negative cytomegalovirus serostatus, and tacrolimus-based prophylaxis. These results provide important information to guide the choice of graft sources and are benchmarks for future graft-versus-host disease prophylaxis studies.

    UR - http://www.scopus.com/inward/record.url?scp=85001975354&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85001975354&partnerID=8YFLogxK

    U2 - 10.3324/haematol.2016.149427

    DO - 10.3324/haematol.2016.149427

    M3 - Article

    C2 - 27662017

    AN - SCOPUS:85001975354

    VL - 101

    SP - 1592

    EP - 1602

    JO - Haematologica

    JF - Haematologica

    SN - 0390-6078

    IS - 12

    ER -